1-6 of 6
Jorge DiMartino
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Konstanze Döhner, Hartmut Döhner, Daniela Weber, Silke Kapp-Schwoerer, Amanda Gilkes, Ian Thomas, Sean Johnson, Nicola Potter, Yana Bevan, Jad Othman, Nigel H. Russell, Christoph Röllig, Christian Thiede, Martin Bornhaeuser, Thomas Oellerich, Jenna Elder, Luis A. Carvajal, Zung To, Jorge DiMartino, Richard Dillon
Journal: Blood
Blood (2022) 140 (Supplement 1): 6293–6294.
https://doi.org/10.1182/blood-2022-159212
Published: 2022
Journal Articles

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

Luis A. Carvajal, Michael McKeown, Tressa Hood, Pavan Kumar, Douglas C. Saffran, Jorge DiMartino
Journal: Blood
Blood (2022) 140 (Supplement 1): 5932–5933.
https://doi.org/10.1182/blood-2022-159087
Published: 2022
Journal Articles

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 3377–3378.
https://doi.org/10.1182/blood-2022-159154
Published: 2022
Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

John C. Byrd, Jorge E. Cortes, Mark D. Minden, Thomas Oellerich, Eytan M. Stein, Jenna Elder, Pavan Kumar, Gordon Bray, Jorge DiMartino, Wendy Stock
Journal: Blood
Blood (2021) 138 (Supplement 1): 1282.
https://doi.org/10.1182/blood-2021-145773
Published: 2021
Journal Articles

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

Melinda A. L. Day, Philipp Sergeev, Caroline A. Heckman, Anna Schinzel, Nikolaus D. Obholzer, Charles Y. Lin, Pavan Kumar, Jorge DiMartino, Douglas C. Saffran
Journal: Blood
Blood (2021) 138 (Supplement 1): 3356.
https://doi.org/10.1182/blood-2021-146180
Published: 2021
Journal Articles

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

Clinical Trials & Observations
Eytan M. Stein, Guillermo Garcia-Manero, David A. Rizzieri, Raoul Tibes, Jesus G. Berdeja, Michael R. Savona, Mojca Jongen-Lavrenic, Jessica K. Altman, Blythe Thomson, Stephen J. Blakemore, Scott R. Daigle, Nigel J. Waters, A. Benjamin Suttle, Alicia Clawson, Roy Pollock, Andrei Krivtsov, Scott A. Armstrong, Jorge DiMartino, Eric Hedrick, Bob Löwenberg, Martin S. Tallman
Journal: Blood
Blood (2018) 131 (24): 2661–2669.
https://doi.org/10.1182/blood-2017-12-818948
Published: 2018
Includes: Supplemental data